Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. [electronic resource]
Producer: 20190805Description: 1668-1674 p. digitalISSN:- 1527-7755
- Aged
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Agents, Immunological -- administration & dosage
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cohort Studies
- Disease-Free Survival
- Female
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Melanoma -- drug therapy
- Middle Aged
- Neoplasm Metastasis
- Skin Neoplasms -- drug therapy
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.